Pacira Pharma (PCRX) Misses Q1 EPS by 4c

Pacira Pharma (NASDAQ: PCRX) reported Q1 EPS of $0.22, $0.04 worse than the analyst estimate of $0.26. Revenue for the quarter came in at $91.3 million versus the consensus estimate of $91.69 million.

2019 Financial Guidance

Pacira updated its 2019 financial guidance to include net product sales of iovera° (from the April 9, 2019 acquisition date onward) and reiterated all remaining 2019 financial guidance as follows:

• EXPAREL net product sales of $400 million to $410 million.
• iovera° net product sales of $8 million to $10 million.
• Non-GAAP gross margins of 75% to 76%.
• Non-GAAP research and development (R&D) expense of $60 million to $70 million.
• Non-GAAP selling, general and administrative (SG&A) expense of $165 million to $175 million.
• Stock-based compensation of $30 million to $35 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth